<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</h1>
      <div class="meta">2025-09-15 13:00:00+00:00 UTC</div>
      <ul>
        <li>PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorec</li>
        <li>The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY</li>
        <li>The Test runs in a single-use cartridge, requiring less than three minutes of hands-on-time and delivering straightforward results in under three hours.</li>
        <li>“Achieving FDA approval for our Idylla™ CDx MSI Test represents a key milestone for Biocartis,&quot; said Michael Korn, M.D., Chief Medical and Scientific Officer at Biocartis.</li>
        <li>With its speed, accuracy, and automation, the Idylla™ CDx MSI Test offers a powerful solution that enables clinicians to make timely, confident and data-driven treatment decisions when every moment counts.”</li>
        <li>“It underscores our commitment to helping oncology patients receive the right therapy without delay and the recent CheckMate-8HW data reinforce the critical importance of accurate MSI-H/dMMR testing in colorectal cancer.</li>
        <li>“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection of our Precision Medicine strategy at Brist</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/press-release-biocartis-nv-biocartis-receives-fda-approval-for-the-idylla-cdx-ms/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=Press+Release+Biocartis+NV%3A+Biocartis+Receives+FDA+Approval+for+the+Idylla%E2%84%A2+CDx+MSI+Test%0A%E2%80%A2+PRESS+RELEASE+-+09%2F15%2F2025%2C+09%3A00+AM+EDT+Biocartis+Receives+FDA+Approval+for+the+Idylla%E2%84%A2+CDx+MSI+Test+First-ever+fully+automated%2C+sample-to-result%2C+cartridge-based%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fpress-release-biocartis-nv-biocartis-receives-fda-approval-for-the-idylla-cdx-ms%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
